Advertisement

Myeloproliferative Disorders and Myelodysplastic Syndromes

  • Jo-Anne Vergilio
  • Adam Bagg
Chapter

Abstract

The myeloproliferative disorders (MPD) and myelodysplastic syndromes (MDS) encompass a pathologically and clinically heterogeneous group of hematologic entities that are united by their putative origin from pluripotent hematopoietic stem cells. The World Health Organization classifies these entities into three broad categories: (1) the chronic myeloproliferative diseases, (2) the myelodysplastic syndromes, and (3) the myelodysplastic/myeloproliferative diseases1 (see Table 35-1). Though all are true hematopoietic stem cell disorders characteristically associated with bone marrow hyperplasia, they are divergent in that MPD typically are associated with effective hematopoiesis, while MDS are associated with ineffective hematopoiesis, reflected by high or low peripheral blood counts, respectively.

Keywords

Chronic Myeloid Leukemia Myelodysplastic Syndrome Chronic Myelogenous Leukemia Imatinib Mesylate Polycythemia Vera 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours, Pathology and Genetics, Tumours of Haematopoetic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.Google Scholar
  2. 2.
    Nowell PC. Progress with chronic myelogenous leukemia: a personal perspective over four decades. Annu Rev Med. 2002;53:1–13.PubMedCrossRefGoogle Scholar
  3. 3.
    Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukemia. Acta Haematol. 2002;108:180–202.PubMedCrossRefGoogle Scholar
  4. 4.
    Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;93:3167–3215.Google Scholar
  5. 5.
    Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337–1354.PubMedCrossRefGoogle Scholar
  6. 6.
    Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88:2410–2414.PubMedGoogle Scholar
  7. 7.
    Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313–317.PubMedCrossRefGoogle Scholar
  8. 8.
    Shepter PJ, Ben-Yehuda D. Molecular evolution of chronic myeloid leukaemia. Semin Cancer Biol. 2001;11:313–322.CrossRefGoogle Scholar
  9. 9.
    Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010–4022.PubMedCrossRefGoogle Scholar
  10. 10.
    Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003;102:1160–1168.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaeda J, Chase A, Goldman JM. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukemia. Acta Haematol. 2002;107:64–75.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Dwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med. 2002;53:369–381.PubMedCrossRefGoogle Scholar
  14. 14.
    Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160–166.PubMedGoogle Scholar
  15. 15.
    O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Eng J Med. 2003;348:994–1004.CrossRefGoogle Scholar
  16. 16.
    Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17:2401–2409.PubMedCrossRefGoogle Scholar
  17. 17.
    Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Eng J Med. 2003;349:1423–1432.CrossRefGoogle Scholar
  18. 18.
    Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873–2878.PubMedCrossRefGoogle Scholar
  19. 19.
    Kantarjian HM, O’Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033–1041.PubMedCrossRefGoogle Scholar
  20. 20.
    Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–2653.PubMedCrossRefGoogle Scholar
  21. 21.
    Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma. 2003;44:23–28.PubMedCrossRefGoogle Scholar
  22. 22.
    Tsao AS, Kantarjian H, Talpaz DM. STI-571 in chronic myelogenous leukemia. Br J Haematol. 2002;119:15–24.PubMedCrossRefGoogle Scholar
  23. 23.
    Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell. 2002;2:99–102.PubMedCrossRefGoogle Scholar
  24. 24.
    Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926–2932.PubMedCrossRefGoogle Scholar
  25. 25.
    Wang YL, Bagg A, Pear W, et al. Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer. 2001;32:97–111.PubMedCrossRefGoogle Scholar
  26. 26.
    Bagg A. Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. J Mol Diag. 2002;4:1–10.Google Scholar
  27. 27.
    Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107:587–599.PubMedCrossRefGoogle Scholar
  28. 28.
    Hochhaus A. Detection and quantification of leukemia-specific rearrangements. In: Boultwood J, Fidler C, eds. Methods in Molecular Medicine. Totowa, NJ: Humana Press; 2002:67–96.Google Scholar
  29. 29.
    Branford S, Hughes TP, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. Br J Haematol. 2002;117:875–877.PubMedCrossRefGoogle Scholar
  30. 30.
    Lichty BD, Keating A, Callum J, et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol. 1998;103:711–715.PubMedCrossRefGoogle Scholar
  31. 31.
    Kreuzer KA, Lass U, Bohn A, et al. LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res. 1999;59:3171–3174.PubMedGoogle Scholar
  32. 32.
    Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13:1825–1832.PubMedCrossRefGoogle Scholar
  33. 33.
    Serrano J, Roman J, Sanchez J, et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 (BCR-ABL) and p190 (BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190 (BCR-ABL) detection precede cytogenetic relapse. Blood. 2000;95:2659–2665.PubMedGoogle Scholar
  34. 34.
    Formankova R, Honzatkova L, Moravcova J, et al. Prediction and reversion of post-transplant relapse in patients with chronic myeloid leukemia using mixed chimerism and residual disease detection and adoptive immunotherapy. Leuk Res. 2000;24:339–347.PubMedCrossRefGoogle Scholar
  35. 35.
    Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in cells of some healthy individuals. Blood. 1995;86:3118–3122.PubMedGoogle Scholar
  36. 36.
    Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362–3367.PubMedGoogle Scholar
  37. 37.
    Radich JP, Gehley G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85:2632–2638.PubMedGoogle Scholar
  38. 38.
    Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood. 2001;98:1701–1707PubMedCrossRefGoogle Scholar
  39. 39.
    Chomel JC, Brizard F, Veinstein A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood. 2000;95:404–408.PubMedGoogle Scholar
  40. 40.
    Lion T. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia: The European Investigators on Chronic Myelogenous Leukemia Group. Bone Marrow Transplant. 1994;14:505–509.PubMedGoogle Scholar
  41. 41.
    Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120:990–999.PubMedCrossRefGoogle Scholar
  42. 42.
    Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 2005;19:507–512.PubMedGoogle Scholar
  43. 43.
    Tipping AJ, Deininger MW, Goldman JM, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol. 2003;31:1073–1080.PubMedGoogle Scholar
  44. 44.
    Vergilio J, Bagg A. Chronic myeloid leukemia: Molecular diagnosis and monitoring. In: Fuchs J, Podda M, eds. Encyclopedia of Medical Genomics and Proteomics. New York: Marcel Dekker; 2005.Google Scholar
  45. 45.
    Goldman J. Monitoring minimal residual disease in BCR-ABLpositive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol. 2005;12:33–39.PubMedCrossRefGoogle Scholar
  46. 46.
    O’Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003;17:481–487.PubMedCrossRefGoogle Scholar
  47. 47.
    Saussele S, Weisser A, Muller MC, et al. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia. 2000;14:2006–2010.PubMedCrossRefGoogle Scholar
  48. 48.
    Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol. 2004;11:51–57.PubMedCrossRefGoogle Scholar
  49. 49.
    Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med. 2005;352:1744–1746.PubMedCrossRefGoogle Scholar
  50. 50.
    Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005;80:947–958.PubMedCrossRefGoogle Scholar
  51. 51.
    Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272–4290.PubMedCrossRefGoogle Scholar
  52. 52.
    Harrison CN. Current trends in essential thrombocythemia. Br J Haematol. 2002;117:796–808.PubMedCrossRefGoogle Scholar
  53. 53.
    Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol. 2002;108:55–65.PubMedCrossRefGoogle Scholar
  54. 54.
    Vergilio J, Bagg A. Myelodysplastic syndromes: contemporary biologic concepts and emerging diagnostic approaches. Am J Clin Pathol. 2003;199(suppl):S58–S77.Google Scholar
  55. 55.
    Greiner TC. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders. Am J Clin Pathol. 2006;125:651–653.PubMedGoogle Scholar
  56. 56.
    Cherian S, Bagg A. The genetics of the myelodysplastic syndromes: Classical cytogenetics and recent molecular insights. Hematology. 2006;11:1–13.PubMedCrossRefGoogle Scholar
  57. 57.
    Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107:101–107.PubMedCrossRefGoogle Scholar
  58. 58.
    Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31–35: role of the platelet-derived growth factor receptor Beta. Acta Haematol. 2002;107:113–122.PubMedCrossRefGoogle Scholar
  59. 59.
    Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298–4300.PubMedCrossRefGoogle Scholar
  60. 60.
    Gupta R, Bain BJ, Knight CL. Cytogenetic and molecular genetic abnormalities in systemic mastocytosis. Acta Haematol. 2002;107:123–128.PubMedCrossRefGoogle Scholar
  61. 61.
    Padua RA, West RR. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol. 2000;111:873–874.PubMedCrossRefGoogle Scholar
  62. 62.
    Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep. 2004;3:203–209.PubMedGoogle Scholar
  63. 63.
    Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Eng J Med. 1997;336:1713–1720.CrossRefGoogle Scholar
  64. 64.
    Kita-Sasai Y, Horiike S, Misawa S, et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndromes. Br J Haematol. 2001;115:309–312.PubMedCrossRefGoogle Scholar
  65. 65.
    Lai JL, Preudhomme C, Roumier C, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia. 1995;9:370–381.PubMedGoogle Scholar
  66. 66.
    Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndromes. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 1998;91:1008–1015.PubMedGoogle Scholar
  67. 67.
    Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985–2990.PubMedGoogle Scholar
  68. 68.
    Tien H-F, Tang J-L, Tsay W, et al. Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148–154.PubMedCrossRefGoogle Scholar
  69. 69.
    Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 1998;12:887–892.PubMedCrossRefGoogle Scholar
  70. 70.
    Slovak ML, Bedell V, Popplewell L, et al. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: a report from an international workshop. Genes Chromosomes Cancer. 2002;33:379–394.PubMedCrossRefGoogle Scholar
  71. 71.
    Reddy PL, Sheet VT, Dutt D, et al. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol. 2002;116:564–575.PubMedCrossRefGoogle Scholar
  72. 72.
    Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res. 2000;24:141–151.PubMedCrossRefGoogle Scholar
  73. 73.
    Gale RE. Evaluation of clonality in myeloid stem-cell disorders. Semin Hematol. 1999;36:361–372.PubMedGoogle Scholar
  74. 74.
    Allen RC, Zoghbi HY, Moseley AB, et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229–1239.PubMedGoogle Scholar
  75. 75.
    Uchida T, Ohashi H, Aoki E, et al. Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARAMSP). Leukemia. 2000;14:207–212.PubMedCrossRefGoogle Scholar
  76. 76.
    Briere J, el-Kassar N. Clonality markers in polycythaemia and primary thrombocythaemia. Baillieres Clin Haematol. 1998;11:787–801.PubMedCrossRefGoogle Scholar
  77. 77.
    Klippel S, Strunck E, Busse CE, et al. Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood. 2002;100:2441–2448.PubMedCrossRefGoogle Scholar
  78. 78.
    Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Jo-Anne Vergilio
    • 1
  • Adam Bagg
    • 2
  1. 1.Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.Hematology, Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations